Literature DB >> 12714194

Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation.

Angelo A V de Paola1, Edilberto Figueiredo, Ricardo Sesso, Henrique H Veloso, Luiz Olympio T Nascimento.   

Abstract

BACKGROUND: Atrial fibrillation is the most common sustained cardiac arrhythmia and has an important impact on costs of medical assistance. Traditional interventions to convert atrial fibrillation to sinus rhythm are antiarrhythmic drugs and external electrical cardioversion. However, the best option for starting the cardioversion is not well established.
METHODS: In a multicentre randomised trial of 139 patients with persistent atrial fibrillation lasting less than 6 months, we compared the effectiveness and the cost-effectiveness ratio of initial treatment with chemical or electrical cardioversion. Subjects who did not achieve sinus rhythm with chemical cardioversion were considered to undergo electrical cardioversion and vice-versa.
RESULTS: The efficacy of the initial attempt for cardioversion was similar with chemical or electrical cardioversion (74 vs. 73%, P=0.95). However, the strategy of starting with antiarrhythmic drugs was more effective than with electrical procedure (96 vs. 84%, P=0.0016). Initiating with chemical cardioversion was also less expensive than with electrical cardioversion (1240 US dollars vs. 1917 US dollars ; P=0.002). Life-threatening complications occurred only during chemical cardioversion (5%), all of them in patients with structural heart disease.
CONCLUSIONS: In patients with persistent atrial fibrillation of less than 6 months, initial chemical or electrical cardioversion appear to be similar but the strategy of starting the cardioversion with antiarrhythmic drugs is more effective and less expensive than starting with the electrical procedure. Patients with structural heart disease undergoing chemical cardioversion seem to be more susceptible to severe complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714194     DOI: 10.1016/s0167-5273(02)00380-7

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.

Authors:  P Korantzopoulos; T M Kolettis; A Papathanasiou; K K Naka; P Kolios; I Leontaridis; A Draganigos; C S Katsouras; J A Goudevenos
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

Review 2.  Rhythm control and cardioversion.

Authors:  N Sulke; F Sayers; G Y H Lip
Journal:  Heart       Date:  2006-09-08       Impact factor: 5.994

3.  Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation.

Authors:  Zengxiang Dong; Hong Yao; Zhuangzhuang Miao; Hao Wang; Rongsheng Xie; Ye Wang; Yingfang Shang; Chunlin Gong; Zhaoguang Liang
Journal:  Biomed Rep       Date:  2017-04-20

Review 4.  Pharmacological cardioversion of atrial fibrillation: current management and treatment options.

Authors:  Giuseppe Boriani; Igor Diemberger; Mauro Biffi; Cristian Martignani; Angelo Branzi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation.

Authors:  Bernd Brüggenjürgen; Stefan Kohler; Nadja Ezzat; Thomas Reinhold; Stefan N Willich
Journal:  Pharmacoeconomics       Date:  2013-03       Impact factor: 4.981

Review 6.  Diagnosis and Therapy of Atrial Fibrillation: The Past, The Present and The Future.

Authors:  Denise M S van Marion; Eva A H Lanters; Marit Wiersma; Maurits A Allessie; Bianca B J J M Brundel; Natasja M S de Groot
Journal:  J Atr Fibrillation       Date:  2015-08-31

7.  DC cardioversion of atrial fibrillation and atrial flutter in the emergency department: improving specialist protocols for the generalist.

Authors:  Alexander Carpenter; Sabrina Sargent
Journal:  BMJ Open Qual       Date:  2018-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.